Congenital Adrenal Hyperplasia (CAH) Therapeutic Market Size
Market Size in USD Mn
CAGR6.00%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 6.00% |
| Market Concentration | Medium |
| Major Players | Diurnal Group plc, Spruce Biosciences, Inc., Neurocrine Biosciences, Inc., Millendo Therapeutics, Adrenas Therapeutics, Inc. and Among Others |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Congenital Adrenal Hyperplasia (CAH) Therapeutic Market Analysis
The congenital adrenal hyperplasia (CAH) therapeutic market is estimated to be valued at USD 392.5 million in 2025 and is expected to reach USD 590.2 million by 2032, growing at a compound annual growth rate (CAGR) of 6.00% from 2025 to 2032. The market has seen steady growth in recent years and is expected to continue growing moderately over the forecast period due to increasing treatment rates and demand for specialized drugs to manage the condition.